ProCE Banner Activity

New Advances in Relapsed/Refractory Multiple Myeloma: Frequently Asked Questions on Current and Emerging Treatments

Podcast Episodes
In this podcast episode, listen to myeloma experts Natalie S. Callander, MD, and Shaji Kumar, MD, respond to audience questions from a live CCO Webinar discussing current guidelines and treatment advances for patients with relapsed/refractory multiple myeloma.

Released: September 01, 2020

Expiration: August 31, 2021

Share

Faculty

Natalie S. Callander

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Shaji K. Kumar

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

GlaxoSmithKline LLC

Sanofi Genzyme Corp

Program Director Disclosure

Program Director

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Shaji Kumar, MD, has disclosed that he has received funds for research (paid to the institution) from AbbVie, Amgen, Bristol-Myers Squibb, Celgene, Janssen, Kite, MedImmune, Merck, Novartis, Roche/Genentech, Sanofi, and Takeda and consulting fees from AbbVie, Adaptive, Amgen, Celgene, Genentech, Janssen, Kite, MedImmune, Merck, Oncopeptides, and Takeda.

Faculty Disclosure

Primary Author

Natalie S. Callander, MD

Professor of Medicine
School of Medicine and Public Health
University of Wisconsin
Director, Myeloma Clinical Program
University of Wisconsin Carbone Cancer Center
Madison, Wisconsin

Natalie S. Callander, MD, has disclosed that she has received consulting fees from Cellectar.

Staff Disclosure

Staff

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.